Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS

Riccetti, Nicola; Blettner, Maria; Taylor, Katherine; Wehler, Beatrice; Gohrbandt, Bernhard; Nestle, Ursula; Bals, Robert; Stockinger, Marcus; Wehler, Thomas; Schnittger, Susanne; Eichler, Martin

doi:10.1007/s00432-022-03975-6

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are in accordance with the findings of previous RTCs. 98 Therefore, optimal management is essential, and not less important than the treatment of chemotherapy-related AEs. 30 , 98 Tolerability-guided dose modifications may enable patients to continue treatment without an impact on effectiveness.…”

Section: Qol Of the Patients Who Are Receiving Egfr-tkismentioning

confidence: 99%

Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma

Cárdenas-Fernández,

Soberanis Pina,

Turcott

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

The identification of Epidermal Growth Factor Receptor (EGFR) mutations in lung adenocarcinoma has facilitated the development of personalized medicine based on oncogenic drivers. EGFR-Tyrosine Kinase Inhibitors (TKIs) are part of the targeted therapy; they impede the phosphorylation of the intracellular tyrosine kinase component of EGFR and consequently block signal transduction pathways. These drugs inhibit the proliferation and survival of tumor cells, leading to long-term progression-free survival and overall survival. Diarrhea is one of the most frequent adverse events associated with EGFR-TKIs, affecting at least 18% of patients and reaching up to 95% in some cases. Diarrhea should be managed carefully given its association with important complications, treatment interruptions, and dose reductions. Moreover, nutritional status and quality of life (QoL) can deteriorate due to severe diarrhea. Changes in diet, such as increment of fiber, supplementation with glutamine, and use of probiotics, may contribute to a decrease in the incidence of diarrhea. Improving the control of diarrhea can provide a significant benefit to the QoL of patients.

show abstract

Section: Qol Of the Patients Who Are Receiving Egfr-tkismentioning

confidence: 99%

Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma

Cárdenas-Fernández,

Soberanis Pina,

Turcott

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

Gulikers,

Bruinsma,

Schoenmaekers

et al. 2024

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: Tyrosine kinase inhibitors (TKIs) have significantly improved treatment-related outcomes of patients with oncogene-driven non-small-cell lung cancer (NSCLC). TKIs are usually well tolerated and used for a prolonged time, although experienced toxicity varies between patients. It is unclear whether patients report all (low grade) toxicities and how these impact their daily lives. The use of therapeutic drug monitoring (TDM) to, for example, manage toxicities is increasingly applied, but there is limited insight into the patient perspective regarding TDM. This qualitative study aims to explore patient perspectives on TKI toxicity and TDM. Methods: Five semi-structured focus group interviews were held, each with three to four patients with NSCLC using a TKI and their (care) partners. Two researchers independently performed a directive content analysis. Results: In total, 16 patients and 12 (care) partners participated. Experienced treatment-related toxicities were encountered limitedly and patients felt no boundaries discussing these with their treatment team. However, symptoms were sometimes not reported as they were doubted as treatment related. The concept of TDM-guided dosing to, for example, reduce TKI exposure to account for dosing outside the therapeutic window resulted in feelings of uncertainty regarding treatment efficacy. Patients emphasized the need for thorough research and frequent check-ups to ensure treatment efficacy. Conclusion: Perceived TKI-related toxicities seem limited, although the treatment team should pay attention to symptoms not directly described by patients as treatment related. In general, patients are open to implement TDM-guided dosing, but only if thorough scientific evidence demonstrates retained or enhanced safety and efficacy.

show abstract

Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS

Cited by 2 publications

References 32 publications

Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma

Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma

Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

Contact Info

Product

Resources

About